Heart healthy equals prostate healthy equals statins: The next cancer chemoprevention trial. Part I

Current Opinion in Urology

Volumn 15, Issue 1, 2005, Pages 1-6

  Moyad, Mark A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Aspirin; Cholesterol; Fish oil; Prostate cancer; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; ATORVASTATIN; CHOLESTEROL; FISH OIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PACLITAXEL; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; SCAVENGER RECEPTOR BI; SIMVASTATIN;

ALZHEIMER DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; CROHN DISEASE; DYSLIPIDEMIA; HUMAN; LIFESTYLE; LINSEED; LOW FAT DIET; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

ANTICARCINOGENIC AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 12144267412     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200501000-00002     Document Type: Review

References (44)

1. Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin N Am 2004; 31:289-300. This is one of the first comprehensive and so called 'bottom line' recommendation manuscripts for the clinician attempting to provide simple lifestyle recommendations to men attempting to impact prostate cancer through lifestyle changes. It essentially reviews the overall finding that heart healthy equals prostate healthy.
2. Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention? Urol Clin N Am 2004; 31:301-311. This is one of the first comprehensive and so called 'bottom line' recommendation manuscripts for the clinician attempting to provide simple lifestyle recommendations to men attempting to impact prostate cancer through lifestyle changes. It essentially reviews the overall finding that heart healthy equals prostate healthy.
3. Moyad MA. The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part I: lifestyle changes. Curr Opin Urol 2003; 13:137-145.
4. Moyad MA. The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part II: rapid review of dietary supplements. Curr Opin Urol 2003; 13:147-151.
5. Ornish D, Fair W, Pettengill E, et al. Can lifestyle changes reverse prostate cancer? [abstract]. J Urol 2003; 169:74.
6. Demark-Wahnefried W, Price DT, Polascik TJ, et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 2001; 58:47-52.
7. Demark-Wahnefried W, Robertson CN, Walther PJ, et al. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004; 63:900-904. This was one of the first ever life-style intervention studies that demonstrated an ability to not only reduce the risk of prostate cancer, but that also improve heart health. In addition, this is a cheap and easy to follow intervention that should be discussed with many patients. Powdered flaxseed and a low-fat diet not only reduce PSA and markers of high-risk prostate cancer, but also significantly reduced cholesterol levels in men.
8. Shike M, Latkany L, Riedel E, et al. Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol 2002; 20:3592-3598.
9. Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology 2002; 59 (Suppl 4A):9-19.
10. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000; 92:613-621.
11. Senior K. Atherosclerosis gene increases susceptibility to prostate cancer. Lancet 2002; 360:928.
12. Sonnleithner M, Jeschke K, Bayer L, et al. Dyslipoproteinemia as a risk factor in prostate cancer [abstract]. J Urol 2003; 169:76.
13. Graaf MR, Beiderbeck AB, Egberts ACG, et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22:2388-2394. One of the largest and best case-control studies suggested that statin use may reduce the risk of cancer by 20%. However, one of the largest reductions in risk was observed for prostate cancer (63% reduction), which again makes statin drugs one of the most ideal chemoprevention agents to test in a future randomized trial.
14. Shannon J, Garzotto M, Palma AJ. Statin use and prostate cancer risk [abstract]. Proc Annu Meet Am Assoc Cancer Res 2004; 23:404.
15. Poynter JN, Rennert G, Bonner JD, et al. HMG CoA reductase inhibitors and the risk of colorectal cancer [abstract]. Proc Annu Meet Am Assoc Cancer Res 2004; 23:1.
16. Katz MO, Zelefsky MJ, Marion C, et al. Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer [abstract]. Proceedings of the 45th Annual ASTRO Meeting, October 18-23, 2003. Salt Lake City, Utah. Volume 57, issue 2. American Society of Clinical Oncology (publisher/organizer). p. S271.
17. Freeman MR. Solomon KR. Cholesterol and prostate cancer. J Cellular Biochem 2004; 91:54-69. This is one of the first and best reviews of cholesterol and prostate cancer risk that has been published. This article carefully and methodically takes the reader through most of the basic science and clinical data that suggest a cholesterol and prostate cancer link. However, the article is also very objective in its assessment.
18. White RM. On the occurrence of crystals in tumours. J Pathol Bacteriol 1909; 13:3-10.
19. Schaffner CP. Prostatic cholesterol metabolism: Regulation and alteration. In: Alan R, editor. The prostatic cell: Structure and function. New York: Liss, Inc. 1981; pp. 279-324.
20. Farina HG, Bublik DR, Alonso DF, Gomez DE. Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 2002; 19:551-559.
21. Ukomadu C, Dutta A. Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem 2003; 278:4840-4846.
22. Wong WW, Tan MM, Xia Z, et al. Cervistatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001; 7:2067-2075.
23. Schaffner CP, Gordon HW. The hypocholesterolemic activity of orally administered polyene macrolides. Proc Natl Acad Sci U S A 1968; 61:36-41.
24. Hughes-Fulford M, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 2001; 22:701-707.
25. Swyer G. The cholesterol content of normal and enlarged prostates. Cancer Res 1942; 2:372-375.
26. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84:886-891.
27. Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockade in men with prostatic carcinoma. Metabolism 1987; 36:244-250.
28. Kraemer FB, Pont A. Inhibition of cholesterol synthesis by ketoconazole. Am J Med 1986; 80:616-622.
29. Stone GW, Ellis SG, Cox DA, et al. For the Taxus-IV investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
30. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Atzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57:1439-1443.
31. Coons JC. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 2002; 36:326-330.
32. Moyad MA. Lifestyle changes to prevent BPH: heart healthy = prostate healthy. Urol Nurs 2003; 23:439-441.
33. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91:230-231.
34. El-Sakka AI, Morsy AM, Fagih BI, Nassar AH. Coronary artery risk factors in patients with erectile dysfunction. J Urol 2004; 172:251-254.
35. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172:255-258.
36. Moyad MA. An introduction to aspirin. NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: Part I. Semin Urol Oncol 2001; 19:294-305.
37. Moyad MA. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: Part II. Semin Urol Oncol 2001; 19:306-316.
38. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291:2433-2440.
39. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77:219-225.
40. Basler JW, Piazza GA, Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004; 171:S59-S63.
41. Harris WS. Fish oil supplementation: evidence for health benefits. Cleve Clin J Med 2004; 71:208-221. This is one of the best reviews of fish oil supplements in the literature. It outlines the argument for the use of this heart healthy agent in a variety of medical disciplines. This article makes a strong argument for using this supplement in many at-risk patients for a variety of chronic diseases.
42. Rodriguez C, Jacobs EJ, Mondul AM, et al. Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 2004; 13:378-382.
43. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004; 22:3705-3712.
44. Coogan PF, Rosenberg L, Palmer JR, et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13:262-267.